Your browser doesn't support javascript.
loading
Long-term results of two consecutive trials in childhood acute lymphoblastic leukaemia performed by the Spanish Cooperative Group for Childhood Acute Lymphoblastic Leukemia Group (SHOP) from 1989 to 1998
Badell, I; Muñoz, A; Estella, J; Fernández-Delgado, R; Javier, G; Verdeguer, A; Cubells, J.
Afiliação
  • Badell, I; Hospital Sant Pau. Barcelona. Spain
  • Muñoz, A; Hospital Ramón y Cajal. Madrid. Spain
  • Estella, J; Hospital San Juan De Dios. Esplugues. Spain
  • Fernández-Delgado, R; Hospital Clínico de Valencia. Valencia. Sàon
  • Javier, G; Hospital Germans Trias i Pujol. Badalona. Spain
  • Verdeguer, A; Hospital La Fe. Madrid. Spain
  • Cubells, J; Hospital Sant Pau. Barcelona. Spain
Clin. transl. oncol. (Print) ; 10(2): 117-124, feb. 2008. tab, ilus
Artigo em Inglês | IBECS | ID: ibc-123418
Biblioteca responsável: ES1.1
Localização: BNCS
ABSTRACT

INTRODUCTION:

The first multi-centric protocol for childhood acute lymphoblastic leukaemia (ALL) treatment in Spain started in 1989 and was conducted by the Spanish Pediatric Hematology and Oncology Societies. MATERIALS AND

METHODS:

A total of 673 patients were included in two consecutive trials, SHOP-89 (1989-1993) and SHOP- 94 (1994-1998). Approximately 67% of the children diagnosed with ALL in Spain during this period were enrolled in these trials. The 250 eligible patients enrolled in the SHOP- 89 study were stratified to either a standard or a high-risk group. Therapy schedule was based on the central nervous system (CNS) therapy designed by St Jude CRH and the Children's Cancer Group, and the post-induction intensification developed by the BFM group. In the SHOP-94 study, a further high-risk group was included in the stratification of the 423 enrolled patients. The therapeutic protocol was characterised by intensification of systemic chemotherapy and the administration of cranial radiotherapy only to patients at high risk of relapse or with CNS involvement at diagnosis.

RESULTS:

Event-free survival (EFS) increased from 0.57+/- 0.03 at 15 years in SHOP-89, to 0.68+/-0.03 at 11 years in SHOP-94 (p=0.01). Relapse rate decreased from SHOP-89 to SHOP-94 0.38 vs. 0.25 (p=0.01). CNS relapse rate was 9.1% in SHOP-89 and 4.6% in SHOP-94 (p=0.001). EFS in patients with T-immunophenotype was 0.40+/-0.08 in SHOP-89 and 0.44+/-0.06 in SHOP-94 (p=ns).

CONCLUSIONS:

Our therapeutic results evidence a significant improvement in EFS and systemic and CNS relapse rates among the two consecutive trials after modification of patient stratification and intensification of systemic chemotherapy (AU)
RESUMEN
No disponible
Assuntos
Buscar no Google
Coleções: Bases de dados nacionais / Espanha Contexto em Saúde: ODS3 - Saúde e Bem-Estar / ODS3 - Meta 3.4 Reduzir as mortes prematuras devido doenças não transmissíveis / ODS3 - Meta 3.2 Reduzir as mortes de recém nascidos e crianças com menos de 5 anos Problema de saúde: Meta 3.2: Reduzir as mortes de recém nascidos e crianças com menos de 5 anos / Leucemia / Doenças Não Transmissíveis Base de dados: IBECS Assunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras B / Protocolos de Quimioterapia Combinada Antineoplásica / Ensaios Clínicos Controlados Aleatórios como Assunto / Estudos Multicêntricos como Assunto Tipo de estudo: Ensaio clínico controlado / Guia de prática clínica Limite: Adolescente / Criança / Criança, pré-escolar / Feminino / Humanos / Lactente / Masculino Idioma: Inglês Revista: Clin. transl. oncol. (Print) Ano de publicação: 2008 Tipo de documento: Artigo Instituição/País de afiliação: Hospital Clínico de Valencia/Sàon / Hospital Germans Trias i Pujol/Spain / Hospital La Fe/Spain / Hospital Ramón y Cajal/Spain / Hospital San Juan De Dios/Spain / Hospital Sant Pau/Spain
Buscar no Google
Coleções: Bases de dados nacionais / Espanha Contexto em Saúde: ODS3 - Saúde e Bem-Estar / ODS3 - Meta 3.4 Reduzir as mortes prematuras devido doenças não transmissíveis / ODS3 - Meta 3.2 Reduzir as mortes de recém nascidos e crianças com menos de 5 anos Problema de saúde: Meta 3.2: Reduzir as mortes de recém nascidos e crianças com menos de 5 anos / Leucemia / Doenças Não Transmissíveis Base de dados: IBECS Assunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras B / Protocolos de Quimioterapia Combinada Antineoplásica / Ensaios Clínicos Controlados Aleatórios como Assunto / Estudos Multicêntricos como Assunto Tipo de estudo: Ensaio clínico controlado / Guia de prática clínica Limite: Adolescente / Criança / Criança, pré-escolar / Feminino / Humanos / Lactente / Masculino Idioma: Inglês Revista: Clin. transl. oncol. (Print) Ano de publicação: 2008 Tipo de documento: Artigo Instituição/País de afiliação: Hospital Clínico de Valencia/Sàon / Hospital Germans Trias i Pujol/Spain / Hospital La Fe/Spain / Hospital Ramón y Cajal/Spain / Hospital San Juan De Dios/Spain / Hospital Sant Pau/Spain
...